4.7 Article

Disease-specific classification using deconvoluted whole blood gene expression

Journal

SCIENTIFIC REPORTS
Volume 6, Issue -, Pages -

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/srep32976

Keywords

-

Funding

  1. Prostate Cancer Foundation [R01AG046170, U01HG008451]

Ask authors/readers for more resources

Blood-based biomarker assays have an advantage in being minimally invasive. Diagnostic and prognostic models built on peripheral blood gene expression have been reported for various types of disease. However, most of these studies focused on only one disease type, and failed to address whether the identified gene expression signature is disease-specific or more widely applicable across diseases. We conducted a meta-analysis of 46 whole blood gene expression datasets covering a wide range of diseases and physiological conditions. Our analysis uncovered a striking overlap of signature genes shared by multiple diseases, driven by an underlying common pattern of cell component change, specifically an increase in myeloid cells and decrease in lymphocytes. These observations reveal the necessity of building disease-specific classifiers that can distinguish different disease types as well as normal controls, and highlight the importance of cell component change in deriving blood gene expression based models. We developed a new strategy to develop blood-based disease-specific models by leveraging both cell component changes and cell molecular state changes, and demonstrate its superiority using independent datasets.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Real-world Characteristics and Outcomes of Patients With Metastatic Castration-resistant Prostate Cancer Receiving Chemotherapy Versus Androgen Receptor-targeted Therapy After Failure of First-line Androgen Receptor-targeted Therapy in the Community Setting

William K. Oh, Raymond Miao, Francis Vekeman, Jennifer Sung, Wendy Y. Cheng, Marjolaine Gauthier-Loiselle, Ravinder Dhawan, Mei Sheng Duh

CLINICAL GENITOURINARY CANCER (2018)

Article Urology & Nephrology

Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer

Li Wang, Yixuan Gong, Abdel Saci, Peter M. Szabo, Alberto Martini, Andrea Necchi, Arlene Siefker-Radtke, Sumanta Pal, Elizabeth R. Plimack, John P. Sfakianos, Nina Bhardwaj, Amir Horowitz, Adam M. Farkas, David Mulholland, Bruce S. Fischer, William K. Oh, Padmanee Sharma, Jun Zhu, Matthew D. Galsky

EUROPEAN UROLOGY (2019)

Review Urology & Nephrology

Programmed Death-1 or Programmed Death Ligand-1 Blockade in Patients with Platinum-resistant Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis

Scot A. Niglio, Rachel Jia, Jiayi Ji, Samuel Ruder, Vaibhav G. Patel, Alberto Martini, John P. Sfakianos, Kathryn E. Marqueen, Nikhil Waingankar, Reza Mehrazin, Peter Wiklund, William K. Oh, Madhu Mazumdar, Bart S. Ferket, Matthew D. Galsky

EUROPEAN UROLOGY (2019)

Article Immunology

The evolving landscape of immunotherapy in advanced prostate cancer

Vaibhav G. Patel, William K. Oh

IMMUNOTHERAPY (2019)

Article Oncology

Prostate Cancer in World Trade Center Responders Demonstrates Evidence of an Inflammatory Cascade

Yixuan Gong, Li Wang, Haocheng Yu, Naomi Alpert, Mitchell D. Cohen, Colette Prophete, Lori Horton, Maureen Sisco, Sung-Hyun Park, Hyun-Wook Lee, Judith Zelikoff, Lung-Chi Chen, Dana Hashim, Mayte Suarez-Farinas, Michael J. Donovan, Stuart A. Aaronson, Matthew Galsky, Jun Zhu, Emanuela Taioli, William K. Oh

MOLECULAR CANCER RESEARCH (2019)

Article Urology & Nephrology

Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019

Silke Gillessena, Gerhardt Attard, Tomasz M. Beer, Himisha Beltran, Anders Bjartell, Alberto Bossi, Alberto Briganti, Rob G. Bristow, Kim N. Chi, Noel Clarke, Ian D. Davis, Johann de Bono, Charles G. Drake, Ignacio Duran, Ros Eeles, Eleni Efstathiou, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Karim Fizazi, Mark Frydenberg, Martin Gleave, Susan Halabi, Axel Heidenreich, Daniel Heinrich, Celestia (Tia) S. Higano, Michael S. Hofman, Maha Hussain, Nicolas James, Ravindran Kanesvaran, Philip Kantoff, Raja B. Khauli, Raya Leibowitz, Chris Logothetis, Fernando Maluf, Robin Millman, Alicia K. Morgans, Michael J. Morris, Nicolas Mottet, Hind Mrabti, Declan G. Murphy, Vedang Murthy, William K. Oh, Piet Ost, Joe M. OSullivan, Anwar R. Padhani, Chris Parker, Darren M. C. Poon, Colin C. Pritchard, Robert E. Reiter, Mack Roach, Mark Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver Sartor, Howard Scher, Neal Shore, Eric Small, Matthew Smith, Howard Soule, Cora N. Sternberg, Thomas Steuber, Hiroyoshi Suzuki, Christopher Sweeneyh, Matthew R. Sydes, Mary-Ellen Taplinh, Bertrand Tombal, Levent Turkeri, Inge van Oort, Almudena Zapatero, Aurelius Omlind

EUROPEAN UROLOGY (2020)

Article Oncology

Surrogate endpoints for overall survival for patients with metastatic hormone-sensitive prostate cancer in the CHAARTED trial

Alberto Martini, John Pfail, Francesco Montorsi, Matthew D. Galsky, William K. Oh

PROSTATE CANCER AND PROSTATIC DISEASES (2020)

Article Oncology

Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA

M. C. Liu, G. R. Oxnard, E. A. Klein, C. Swanton, M. Seiden

ANNALS OF ONCOLOGY (2020)

Article Oncology

Predicting toxicity-related docetaxel discontinuation and overall survival in metastatic castration-resistant prostate cancer: a pooled analysis of open phase 3 clinical trial data

Alberto Martini, Anish B. Parikh, John P. Sfakianos, Francesco Montorsi, Matthew D. Galsky, William K. Oh, Che-Kai Tsao

Summary: Docetaxel is widely used in mCRPC, but its optimal use is unclear. This study aimed to create a predictive model for Docetaxel toxicity-related discontinuation (TRDD) using data from three clinical trials. The model identified three risk groups for TRDD, helping clinicians balance treatment toxicity and efficacy.

PROSTATE CANCER AND PROSTATIC DISEASES (2021)

Article Endocrinology & Metabolism

Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes

Matthew C. Riddle, William T. Cefalu, Philip H. Evans, Hertzel C. Gerstein, Michael A. Nauck, William K. Oh, Amy E. Rothberg, Carel W. le Roux, Francesco Rubino, Philip Schauer, Roy Taylor, Douglas Twenefour

Summary: Improvement of glucose levels in people with diabetes can occur spontaneously or after medical interventions. Newer forms of treatment may lead to more sustained improvement. However, the terminology and objective measures for defining this process are not established, and the long-term risks and benefits are not well understood. An international expert group proposed the term "remission" and HbA1c < 6.5% as the usual diagnostic criterion. They also suggested active observation and further research on predictors and outcomes of remission.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2022)

Review Medicine, General & Internal

Prostate Cancer Dormancy and Reactivation in Bone Marrow

Deepak K. Singh, Vaibhav G. Patel, William K. Oh, Julio A. Aguirre-Ghiso

Summary: Prostate cancer has a variable clinical course, with possibilities ranging from curable local disease to lethal metastatic spread. The dynamic interplay between dormant disseminated cancer cells (DCCs) and the primary tumor microenvironment (TME) as well as the secondary organ niche plays a crucial role in controlling the conversion between states of dormancy and activation.

JOURNAL OF CLINICAL MEDICINE (2021)

Article Oncology

Extraction of Treatment Information From Electronic Health Records and Evaluation of Testosterone Recovery in Patients With Prostate Cancer

Sunny Guin, Tomi Jun, Vaibhav G. Patel, Kristin L. Ayers, Matthew Deitz, Yuqin Cai, Xiang Zhou, Che-Kai Tsao, William K. Oh, Rong Chen, Bobby C. Liaw

Summary: This study utilized machine learning and natural language processing to build a clinical research database and investigate factors influencing testosterone recovery in patients with localized prostate cancer. The results demonstrated the impact of baseline testosterone levels on T-recovery and the association between ADT exposure and T-recovery.

JCO CLINICAL CANCER INFORMATICS (2022)

Article Oncology

Biomarker Development Trial of Satraplatin in Patients with Metastatic Castration-Resistant Prostate Cancer

Bobby C. Liaw, Che-Kai Tsao, Sonia Seng, Tomi Jun, Yixuan Gong, Matthew D. Galsky, William K. Oh

Summary: This study evaluated the feasibility and usefulness of blood-based biomarkers to identify platinum-sensitive mCRPC. Although some biomarkers were assessed, none were significantly associated with response to satraplatin.

ONCOLOGIST (2022)

Article Oncology

CDK12-Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade

Michael T. Schweizer, Gavin Ha, Roman Gulati, Landon Brown, Rana R. McKay, Tanya Dorff, Anna C. H. Hoge, Jonathan Reichel, Pankaj Vats, Deepak Kilari, Vaibhav Patel, William K. Oh, Arul Chinnaiyan, Colin C. Pritchard, Andrew J. Armstrong, R. Bruce Montgomery, Ajjai Alva

JCO PRECISION ONCOLOGY (2020)

No Data Available